TY  - BOOK
AU  - Boyce, Steven W
AU  - Najjar, Samer S
TI  - An examination of survival by sex and race in the HeartWare Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) and continued access protocol trials
SN  - 1053-2498
PY  - 2015///
KW  - *Continental Population Groups
KW  - *Heart Failure/mo [Mortality]
KW  - *Heart Failure/th [Therapy]
KW  - *Heart Transplantation
KW  - *Heart-Assist Devices
KW  - *Sex Factors
KW  - Adult
KW  - Creatinine/bl [Blood]
KW  - Female
KW  - Follow-Up Studies
KW  - Heart Failure/eh [Ethnology]
KW  - Humans
KW  - Hypertension/ep [Epidemiology]
KW  - Incidence
KW  - Kaplan-Meier Estimate
KW  - Length of Stay
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Treatment Outcome
KW  - MedStar Washington Hospital Center
KW  - MedStar Heart Institute
KW  - Comparative Study
KW  - Journal Article
KW  - Multicenter Study
N1  - Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007
N2  - BACKGROUND: The Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) trial was a multicenter, prospective trial of the HeartWare Ventricular Assist Device (HVAD). The performance of the HVAD in various demographic sub-groups was evaluated; CONCLUSIONS: Although heart failure etiology differed between men and women and between whites and non-whites, sex and race were not factors that affected survival in patients receiving the HVAD as BTT, which was high in all sub-groups.Copyright © 2015. Published by Elsevier Inc; METHODS: Baseline characteristics, adverse events, and survival were compared for men vs. women and whites vs. non-whites in the combined ADVANCE BTT and continued access protocol trial. Of 332 patients enrolled in these trials, 236 were men and 96 women, with 228 whites and 104 non-whites; RESULTS: At baseline, women had a smaller body surface area (1.8 +/- 0.2 vs. 2.1 +/- 0.3 m2, p < 0.0001), less hypertension (50.0% vs. 61.9%, p = 0.05), and less ischemic cardiomyopathy (15.6% vs. 45.3%, p < 0.0001). Differences in Kaplan-Meier survival were not significant at 180 days (men, 91.8%; women, 91.7%) and 1 year (men, 85.3%; women, 85.1%) despite adjustment for baseline differences. Men had a lower incidence of early right heart failure and renal and respiratory dysfunction, and a shorter length of stay. In the analysis by race, non-whites were younger than whites and had less ischemic heart failure, more hypertension, and lower creatinine levels at baseline. Non-whites had lower rates of arrhythmia, bleeding requiring rehospitalization, and device malfunctions than whites. Survival was high in non-whites and whites, at 94.1% vs. 90.4% at 180 days and 89.2% vs. 82.8% at 1 year, respectively, despite adjustment for baseline differences
UR  - http://dx.doi.org/10.1016/j.healun.2014.12.011
ER  -